Repurposed Drugs in Cancer Research
This section explores drugs originally developed for non-cancer conditions that are now being investigated for potential applications in cancer research.
These compounds are often discussed within the broader fields of:
- cancer metabolism,
- integrative oncology,
- systems biology,
- and multi-targeted therapeutic research.
Researchers are exploring whether certain existing medications may interact with biological pathways involved in:
- cellular metabolism,
- inflammation,
- angiogenesis,
- immune signalling,
- oxidative stress,
- tumour growth,
- and cellular survival mechanisms.
Interest in drug repurposing has grown significantly in recent years due to the increasing understanding of cancer as a highly complex metabolic and signalling disease.
However, many repurposed drug approaches remain investigational and are still being evaluated in laboratory studies, observational research, and clinical trials.
What Are Repurposed Drugs?
Repurposed drugs — also referred to as drug repositioning — are medications originally approved for one medical condition that are later investigated for potential use in another.
In oncology research, scientists are studying whether some existing drugs may influence biological pathways associated with cancer progression, metabolism, or treatment response.
Examples of drugs commonly discussed in repurposing research include:
- Metformin
- Ivermectin
- Mebendazole
- Doxycycline
- Hydroxychloroquine
- Statins
- Aspirin
- and other established medications.
The level of evidence varies considerably between compounds, cancer types, and research settings.
Why Are Repurposed Drugs Being Studied?
One reason repurposed drugs have attracted attention is that many already have:
- established safety data,
- known pharmacology,
- manufacturing infrastructure,
- and extensive clinical history in humans.
Researchers are exploring whether certain drugs may:
- influence metabolic pathways,
- affect tumour signalling,
- alter inflammation,
- impact angiogenesis,
- modify immune activity,
- or interact with conventional cancer therapies.
Some scientists believe that combining multiple approaches targeting different pathways may represent a promising area for future research.
However, many proposed mechanisms remain theoretical, investigational, or incompletely understood.
The ReDO Project
The ReDO (Repurposing Drugs in Oncology) Project is an international initiative focused on investigating existing non-cancer drugs for potential applications in oncology research.
The project brings together researchers, clinicians, and scientific organisations interested in evaluating:
- published evidence,
- biological mechanisms,
- clinical observations,
- and emerging trial data relating to repurposed drugs.
The ReDO Project has contributed to growing awareness of drug repurposing as an area of scientific and clinical interest.
Researchers involved in the project have published reviews and analyses examining various compounds that may warrant further investigation in oncology settings.
Areas of Research in Drug Repurposing
Identification of Candidate Drugs
Researchers begin by reviewing:
- scientific literature,
- molecular pathway data,
- laboratory findings,
- observational studies,
- and existing clinical evidence.
The goal is to identify drugs that may interact with biological pathways relevant to cancer research.
This process may involve:
- computational modelling,
- pathway analysis,
- preclinical experiments,
- and retrospective clinical observations.
Preclinical Research
Many repurposed drugs are initially studied in:
- cell culture experiments,
- mechanistic models,
- and animal studies
Researchers investigate possible effects involving:
- apoptosis,
- autophagy,
- angiogenesis,
- mitochondrial function,
- oxidative stress,
- immune signalling,
- and cellular metabolism.
It is important to recognise that laboratory findings do not always translate into meaningful clinical outcomes in humans.
Clinical Investigation
Some repurposed drugs progress into:
- early-phase clinical trials,
- observational studies,
- retrospective analyses,
- or combination therapy research.
Clinical investigation aims to better understand:
- safety,
- dosing,
- tolerability,
- interactions,
- and potential therapeutic relevance.
In many cases, evidence remains preliminary or insufficient for broad clinical recommendations.
Combination & Multi-Targeted Approaches
Some researchers are investigating whether repurposed drugs may interact synergistically with:
- chemotherapy,
- radiation therapy,
- immunotherapy,
- ketogenic diets,
- fasting protocols,
- hyperbaric oxygen therapy,
- photobiomodulation,
- and other metabolic strategies.
The concept behind combination approaches is that cancer involves numerous interconnected biological pathways rather than a single target.
Researchers continue exploring whether multi-targeted strategies may influence:
- tumour adaptation,
- metabolic flexibility,
- treatment sensitivity,
- or tumour microenvironment dynamics.
This remains an active and evolving area of investigation.
Safety & Important Considerations
Repurposed drugs are prescription medications and should not be viewed as inherently safe simply because they are already approved for other conditions.
These drugs may still produce:
- side effects,
- toxicities,
- contraindications,
- drug interactions,
- or unintended complications.
The safety profile of a medication may also differ depending on:
- dosage,
- duration,
- combination therapies,
- cancer type,
- organ function,
- and individual patient factors.
Some compounds discussed in repurposing research are not approved for cancer treatment and may only be supported by:
- laboratory evidence,
- theoretical mechanisms,
- case reports,
- or early-stage studies.
Professional medical supervision is essential when considering any prescription medication.
Current State of the Research
Research into repurposed drugs in oncology is expanding rapidly, but levels of evidence vary substantially between compounds.
Some drugs have:
- extensive preclinical literature,
- small clinical studies,
- or observational data,
while others remain highly experimental.
Many questions remain unanswered regarding:
- effectiveness,
- optimal combinations,
- dosing,
- long-term safety,
- patient selection,
- and interactions with conventional therapies.
Large-scale human clinical evidence is still limited for many proposed repurposed drug strategies.
A Research-Focused Educational Approach
This platform aims to organise and explore scientific discussions surrounding:
- cancer metabolism,
- integrative oncology,
- metabolic therapies,
- and investigational repurposed drug research.
Our goal is to present information in a structured and educational format that encourages:
- critical thinking,
- scientific curiosity,
- balanced discussion,
- and informed exploration of emerging research.
No repurposed drug should be interpreted as a guaranteed treatment or substitute for professional medical care.
Cancer biology is highly complex, and responses may vary significantly between individuals.
Explore Related Areas
Repurposed drugs are often discussed alongside other areas of metabolic and integrative cancer research, including:
Educational Disclaimer
The information presented on this page is intended for educational and informational purposes only.
This content explores scientific literature, emerging research, mechanistic findings, and investigational concepts related to repurposed drugs and cancer research.
It is not intended as medical advice, diagnosis, or treatment recommendations.
Always consult qualified healthcare professionals regarding medications, supplements, treatment decisions, or cancer care.